ArticleJournal of oncology practice2015
HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.
Article in Journal of oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- HIV Seroprevalence and Screening Practices Among Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Study From Türkiye.Journal of clinical practice and research · 2026Article
- Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.HIV medicine · 2025Article
- HIV Screening among Patients with Newly Diagnosed Solid and Hematologic Malignancies in a Tertiary Hospital in the Philippines.Acta medica Philippina · 2024Article
- HIV Prevalence and Characteristics Among Patients With AIDS-Defining and Non-AIDS-Defining Cancers in a Tertiary Hospital in Kenya.JCO global oncology · 2023Article
- Cancer Patient Acceptance of HIV Screening at a Large Tertiary Cancer Center.JNCI cancer spectrum · 2022Article
- Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Patterns of HIV Self-Disclosure in the Oncology Setting.JNCI cancer spectrum · 2021Article
- Current evidence on the adoption of indicator condition guided testing for HIV in western countries: A systematic review and meta-analysis.EClinicalMedicine · 2021Article
- Prevalence and predictors of HIV screening in invasive cervical cancer: a 10 year cohort study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020Article
- HIV-Associated Cancers and Related Diseases.The New England journal of medicine · 2018Review
- Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.The oncologist · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy.
methodsWe conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing.
resultsOf 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race.
conclusionThe prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.